With an IPO raise of $625 million, Kailera Therapeutics now holds the new record for the largest public market debut.
Deep Learning with Yacine on MSNOpinion
RLM without recursion: Is it better in reinforcement learning?
A conceptual breakdown exploring whether removing recursion improves reinforcement learning models, focusing on stability, ...
Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...
As Project Hail Mary grips audiences with its mix of science and survival, these five gripping novels offer more journeys ...
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the best medical AI stocks to buy now. On March 31, Recursion moved to ...
OpenAI is rolling out an early version of an artificial intelligence model designed to accelerate drug discovery, joining a ...
Recursion Pharmaceuticals, Inc. (RXRX) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 12:45 PM EDTCompany ParticipantsBen Taylor - ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) stock drops despite market gains: Important facts to note
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.60, marking a -4% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.26%.
According to TipRanks.com, Blum is a 4-star analyst with an average return of 9.1% and a 40.2% success rate. Blum covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., ...
Recursion Pharmaceuticals executives discussed the company’s artificial intelligence-driven drug discovery platform during a ...
Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.
View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results